|
Cellectis S.A. (CLLS) Valeure DCF
FR | Healthcare | Biotechnology | NASDAQ
|
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Cellectis S.A. (CLLS) Bundle
Gardez un aperçu de votre analyse d'évaluation de votre cellule S.A. (CLLS) avec notre calculatrice sophistiquée DCF! Ce modèle Excel est préchargé avec des données CLLS réelles, vous permettant d'ajuster les prévisions et les hypothèses pour des calculs précis de la valeur intrinsèque de Celluctis S.A.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 15.2 | 73.9 | 73.9 | 19.2 | .8 | .6 | .5 | .4 | .3 | .3 |
| Revenue Growth, % | 0 | 386.83 | 0 | -74.08 | -96.06 | -17.53 | -17.53 | -17.53 | -17.53 | -17.53 |
| EBITDA | -105.1 | -34.7 | -86.5 | -76.4 | -92.6 | -.6 | -.5 | -.4 | -.3 | -.3 |
| EBITDA, % | -691.84 | -46.9 | -116.92 | -398.4 | -12269.67 | -89.38 | -89.38 | -89.38 | -89.38 | -89.38 |
| Depreciation | 6.9 | 9.8 | 14.2 | 18.4 | 18.5 | .3 | .3 | .2 | .2 | .2 |
| Depreciation, % | 45.26 | 13.28 | 19.14 | 96.16 | 2453.38 | 54.77 | 54.77 | 54.77 | 54.77 | 54.77 |
| EBIT | -112.0 | -44.5 | -100.6 | -94.8 | -111.2 | -.6 | -.5 | -.4 | -.3 | -.3 |
| EBIT, % | -737.1 | -60.18 | -136.07 | -494.56 | -14723.05 | -92.04 | -92.04 | -92.04 | -92.04 | -92.04 |
| Total Cash | 360.9 | 268.2 | 186.1 | 97.7 | 203.8 | .6 | .5 | .4 | .3 | .3 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 15.3 | 19.2 | 31.1 | 17.6 | 23.1 | .4 | .4 | .3 | .3 | .2 |
| Account Receivables, % | 100.68 | 25.96 | 42.02 | 91.67 | 3063.58 | 71.93 | 71.93 | 71.93 | 71.93 | 71.93 |
| Inventories | 2.9 | 1.6 | .0 | 21.8 | .0 | .2 | .1 | .1 | .1 | .1 |
| Inventories, % | 19.07 | 2.17 | 0 | 113.55 | 0.13245 | 24.28 | 24.28 | 24.28 | 24.28 | 24.28 |
| Accounts Payable | 29.3 | 24.6 | 23.8 | 21.5 | 19.1 | .5 | .4 | .3 | .3 | .2 |
| Accounts Payable, % | 192.65 | 33.28 | 32.13 | 111.92 | 2525.7 | 73.08 | 73.08 | 73.08 | 73.08 | 73.08 |
| Capital Expenditure | -13.0 | -46.3 | -19.7 | -2.4 | -1.1 | -.4 | -.3 | -.2 | -.2 | -.2 |
| Capital Expenditure, % | -85.31 | -62.56 | -26.7 | -12.73 | -142.12 | -57.46 | -57.46 | -57.46 | -57.46 | -57.46 |
| Tax Rate, % | 17.87 | 17.87 | 17.87 | 17.87 | 17.87 | 17.87 | 17.87 | 17.87 | 17.87 | 17.87 |
| EBITAT | -88.1 | -33.1 | -89.1 | -94.9 | -91.3 | -.5 | -.4 | -.3 | -.3 | -.2 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -83.1 | -76.8 | -105.8 | -89.5 | -60.0 | 3.4 | -.4 | -.3 | -.3 | -.2 |
| WACC, % | 11.28 | 11.12 | 11.66 | 12.11 | 11.42 | 11.52 | 11.52 | 11.52 | 11.52 | 11.52 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 2.2 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | -2 | |||||||||
| Present Terminal Value | -1 | |||||||||
| Enterprise Value | 1 | |||||||||
| Net Debt | -44 | |||||||||
| Equity Value | 45 | |||||||||
| Diluted Shares Outstanding, MM | 57 | |||||||||
| Equity Value Per Share | 0.78 |
What You Will Get
- Editable Forecast Inputs: Easily modify key assumptions (growth %, margins, WACC) to explore various scenarios.
- Real-World Data: Cellectis S.A. (CLLS) financial data pre-filled to kickstart your analysis.
- Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value automatically.
- Customizable and Professional: A refined Excel model tailored to meet your valuation requirements.
- Built for Analysts and Investors: Perfect for assessing projections, validating strategies, and enhancing efficiency.
Key Features
- Comprehensive DCF Model: Features both unlevered and levered DCF valuation frameworks tailored for Cellectis S.A. (CLLS).
- WACC Tool: A pre-configured Weighted Average Cost of Capital calculator with adjustable parameters.
- Customizable Forecast Inputs: Easily alter growth projections, capital investments, and discount rates.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios specific to Cellectis S.A. (CLLS).
- Interactive Dashboard and Visuals: Graphical representations of key valuation indicators for straightforward analysis.
How It Works
- Download: Obtain the pre-configured Excel file containing Cellectis S.A.'s (CLLS) financial data.
- Customize: Modify projections, including revenue growth, EBITDA %, and WACC.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Generate various projections and instantly compare results.
- Make Decisions: Utilize the valuation outcomes to inform your investment strategy.
Why Choose This Calculator for Cellectis S.A. (CLLS)?
- Designed for Experts: A sophisticated tool tailored for researchers, biopharma executives, and financial analysts.
- Accurate Data: Cellectis’s historical and anticipated financials preloaded for precise analysis.
- Flexible Scenario Analysis: Effortlessly model various outcomes and assumptions.
- Comprehensive Outputs: Instantly computes intrinsic value, NPV, and essential financial metrics.
- User-Friendly: Step-by-step guidance ensures a smooth experience.
Who Should Use Cellectis S.A. (CLLS)?
- Biotechnology Investors: Make informed decisions with insights into cutting-edge gene-editing technologies.
- Research Analysts: Streamline your analysis with comprehensive data on Cellectis' innovative therapies.
- Healthcare Consultants: Easily tailor presentations or reports focused on the advancements in genetic medicine.
- Life Sciences Enthusiasts: Enhance your knowledge of CAR-T cell therapy and its implications in modern medicine.
- Educators and Students: Utilize it as a hands-on resource for courses in biotechnology and pharmaceutical sciences.
What the Template Contains
- Comprehensive DCF Model: Editable template with detailed valuation calculations tailored for Cellectis S.A. (CLLS).
- Real-World Data: Cellectis S.A.’s historical and projected financials preloaded for analysis.
- Customizable Parameters: Adjust WACC, growth rates, and tax assumptions to test various scenarios.
- Financial Statements: Full annual and quarterly breakdowns for deeper insights into Cellectis S.A. (CLLS).
- Key Ratios: Built-in analysis for profitability, efficiency, and leverage specific to Cellectis S.A. (CLLS).
- Dashboard with Visual Outputs: Charts and tables for clear, actionable results related to Cellectis S.A. (CLLS).
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.